{
    "code": 0,
    "data": [
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Marksans Pharma Limited submits transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06 2026",
            "news_id": "9dcd5d01-6cf6-40ce-ac97-3ef7a828e2bd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebecc4ff-caba-46d7-bfc8-af5f501d091f.pdf",
            "news_date": "2026-02-12 16:03:22",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Marksans Pharma Limited submits transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06 2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebecc4ff-caba-46d7-bfc8-af5f501d091f.pdf",
            "news_date": "2026-02-12 16:03:22"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results",
            "news_id": "8efd18cc-1f65-40be-b0b2-0921369cfa40",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af9e3cc-f480-4488-ac3c-c7925b56faaa.pdf",
            "news_date": "2026-02-06 18:25:54",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af9e3cc-f480-4488-ac3c-c7925b56faaa.pdf",
            "news_date": "2026-02-06 18:25:54"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Un-Audited Financial Results for the Quarter and Nine months ended 31 December 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=273f60d8-833f-4e04-a2b3-2bcb4e6d0651.pdf",
            "news_date": "2026-02-06 16:58:52"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release regarding unaudited financial results for Q3 FY 26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cc16ab9-8b48-4153-afd2-03bb2c345f23.pdf",
            "news_date": "2026-02-05 14:02:21"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Marksans Investors Presentation Q3 and 9M FY 26",
            "news_id": "54d915a4-e2aa-468e-8c39-b0c372f0464e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06ee0731-fe61-4466-9013-15e76d05ed7b.pdf",
            "news_date": "2026-02-05 13:57:15",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Marksans Investors Presentation Q3 and 9M FY 26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06ee0731-fe61-4466-9013-15e76d05ed7b.pdf",
            "news_date": "2026-02-05 13:57:15"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025",
            "news_body": "Unaudited financial results for the quarter and nine months ended 31 December 2025",
            "news_id": "d7f0bcdc-94c3-420b-94e6-99a50d27d638",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=886eea3a-1634-4e4d-a3dd-0c495902a4b7.pdf",
            "news_date": "2026-02-05 13:44:00",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025",
            "news_body": "Unaudited financial results for the quarter and nine months ended 31 December 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=886eea3a-1634-4e4d-a3dd-0c495902a4b7.pdf",
            "news_date": "2026-02-05 13:44:00"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025",
            "news_body": "Outcome of Board Meeting - Unaudited Financial Results for the quarter and nine months ended 31 December 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4699f342-49a2-4ceb-9682-e6c4223df8c4.pdf",
            "news_date": "2026-02-05 13:34:03"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Incorporation of two new wholly owned subsidiary Companies",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=705d202f-cfdb-449b-bff4-e3bfd5ae1d5d.pdf",
            "news_date": "2026-01-27 14:16:22"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "The Company has scheduled a conference call for analysts and investors on Friday February 06 2026 at 04:00 PM (IST) to discuss the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64ecefff-3776-4a78-b867-fbbcde177010.pdf",
            "news_date": "2026-01-22 16:35:46"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate received from RTA under regulation 74(5) of SEBI (DP) regulations 2018 for the quarter ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfe2854a-ad4b-4cb5-8cbc-049005658c45.pdf",
            "news_date": "2026-01-13 15:31:41"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter Ended December 31 2025",
            "news_body": "Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve quarterly results for the Quarter and ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbec6214-f337-46ed-8884-478a3e440c92.pdf",
            "news_date": "2026-01-09 15:32:01"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation for closure of trading window for the quarter ended December 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e37d227c-b28d-4d22-9584-1badef6435f3.pdf",
            "news_date": "2025-12-26 11:49:54"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Marksans Pharma Limited submits Transcript of Investors/analysts meet on Q2 FY26 Unaudited Financial Results held on November 14 2025 at 05:00 pm.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9eeec949-4a87-4c3e-9c42-2eacdadff9d1.pdf",
            "news_date": "2025-11-21 12:13:24"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution from UK MHRA.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c24490ca-3324-4507-b9be-d830d1b2b1d1.pdf",
            "news_date": "2025-11-20 13:06:44"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary Marksans Pharma Inc receives US FDA approval of its ANDA for Loperamide Hydrochloride 2mg tablets.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=817b2022-39fa-4e6f-88b7-1e930d351608.pdf",
            "news_date": "2025-11-19 11:15:40"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d75f1234-0ab3-4c9c-984b-6e83eba4c2a2.pdf",
            "news_date": "2025-11-17 11:18:04"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Newspaper Publication Of Financial Results For The Quarter And Half Year Ended September 30 2025",
            "news_body": "Newspaper cuttings of unaudited financial results of the Company for the quarter and half year ended 30 September 2025 published in Business Standard (English) and Lakshadeep (Marathi) on 15 November 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d0472cc-3464-408c-bc5d-a2ec1d85e83a.pdf",
            "news_date": "2025-11-17 09:44:20"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording upload intimation with respect to investors /analysts meet regarding Q2 FY26 unaudited financial results",
            "news_id": "b719eb7c-e9a9-4aad-a98d-64f83308b701",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9debd3e1-3efd-4d2b-832f-e88e6d24083f.pdf",
            "news_date": "2025-11-14 19:56:34",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording upload intimation with respect to investors /analysts meet regarding Q2 FY26 unaudited financial results",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9debd3e1-3efd-4d2b-832f-e88e6d24083f.pdf",
            "news_date": "2025-11-14 19:56:34"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limited makes a Press Release regarding unaudited financial results for Q2 FY26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e7a1c24-e064-4c24-a3d0-2462a887f199.pdf",
            "news_date": "2025-11-13 19:47:37"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Marksans Pharma Limited Investor Presentation for Q2 FY26",
            "news_id": "580b2f8e-05ec-4663-9367-af71f92750e6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=561963c2-f7bd-403c-8ef9-fe5811634512.pdf",
            "news_date": "2025-11-13 19:42:16",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Marksans Pharma Limited Investor Presentation for Q2 FY26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=561963c2-f7bd-403c-8ef9-fe5811634512.pdf",
            "news_date": "2025-11-13 19:42:16"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025",
            "news_body": "Unaudited Financial Results both standalone and consolidated for the quarter and half year ended 30 September 2025",
            "news_id": "6d2e70fc-5987-44cf-949e-d30597e575c3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b17921f2-848b-43b5-b5dc-6ce569651876.pdf",
            "news_date": "2025-11-13 19:38:46",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025",
            "news_body": "Unaudited Financial Results both standalone and consolidated for the quarter and half year ended 30 September 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b17921f2-848b-43b5-b5dc-6ce569651876.pdf",
            "news_date": "2025-11-13 19:38:46"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025",
            "news_body": "Approval of Unaudited Financial Results both standalone and consolidated for the quarter and half year ended 30 September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af651aa6-603d-48c5-b518-d390f311a5c3.pdf",
            "news_date": "2025-11-13 19:29:27"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Observance Of Vigilance Awareness Week 2025 At Marksans Pharma Limited",
            "news_body": "In line with the initiative of Central Vigilance Commission regarding observance of Vigilance Awareness Week 2025 by taking integrity pledge Marksans appeal to all its shareholders and other stakeholders to take e-pledge.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1947b86-07db-4ef7-a5a1-1006e6fe1d08.pdf",
            "news_date": "2025-11-10 14:32:10"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "US FDA conducts cGMP inspection of Companys 2nd manufacturing facility located at Plot No. A-1 Phase 1-A Verna Industrial Estate Verna Goa with zero Form 483 observation.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3995cb4-2b9d-4796-a3a8-9288edce7b29.pdf",
            "news_date": "2025-11-10 12:05:53"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Ltds wholly owned subsidiary Relonchem Ltd in the UK receives Marketing Authorisation for its product Exemestane 25mg film coated tablet from UK MHRA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=039ebbf3-8aa3-4924-8a67-a5c987f202bf.pdf",
            "news_date": "2025-11-05 09:10:01"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "DISCLOSURE REGARDING 100 DAY CAMPAIGN - \"SAKSHAM NIVESHAK\"",
            "news_body": "Notification for all shareholders regarding the last stage of 100 days campaign.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5d30f34-f0a0-4a06-b434-db4bdf5f7829.pdf",
            "news_date": "2025-11-03 12:13:27"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "The Company has scheduled a conference call for analysts and investors on Friday November 14 2025 at 05:00 PM (IST) to discuss the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6f79a5b-7508-431c-b10d-288fd3a0a5da.pdf",
            "news_date": "2025-10-31 11:41:18"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "ESG Score By CFC Finlease Private Limited (Voluntary)",
            "news_body": "CFC Finlease Private Limited  a SEBI lincensed ESG Rating Provider has voluntarily reviewed ESG rating on the Company based on data available in public domain for fiscal 2025 and assigned an ESG Score of \"73\".",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=78b5b5bd-5e0f-443b-9166-09e0c21e00ff.pdf",
            "news_date": "2025-10-27 10:22:34"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter And Nine Months Ended September 30 2025",
            "news_body": "Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve quarterly results for the Quarter and Nine Months ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3e98ae3-14c2-49ac-883a-675d0baa4705.pdf",
            "news_date": "2025-10-23 16:59:58"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for it products from UK MHRA.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74ecc025-abb1-4982-9804-c1a4628514dc.pdf",
            "news_date": "2025-10-15 13:54:10"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate received from RTA under 74(5) for the quarter and half year ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f35e13b-2273-4f82-9fb3-f6a3ef9222a3.pdf",
            "news_date": "2025-10-13 11:33:20"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Credit Rating",
            "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
            "news_body": "CARE Ratings Limited have upgraded and reaffirmed outlook for the Long term and Short term Bank Facilities",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef15ee1b-21c5-4fa0-94a5-f4e62e429c20.pdf",
            "news_date": "2025-10-08 10:53:39"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "DISCLOSURE REGARDING 100 DAY CAMPAIGN - \"SAKSHAM NIVESHAK\"",
            "news_body": "100 days campaign notification for all shareholders",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9621e0a7-776a-401b-9a48-072b3b73ac2e.pdf",
            "news_date": "2025-10-06 15:03:24"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation for closure of trading window for the quarter and half year ended September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed8c7c5c-576b-4ca6-a4df-b28694a87145.pdf",
            "news_date": "2025-09-25 14:19:32"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Grant Of ESOP Under Marksans Employees Stock Option Scheme 2024 (Scheme)",
            "news_body": "The Nomination and Remuneration Committee (designated Compensation Committee) considered and approved the grant of 400000 option to eligible employees.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=422fe7ab-01d4-439a-b2b8-71b955411de7.pdf",
            "news_date": "2025-09-24 16:51:07"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Ltds subsidiary Relonchem Limited in UK receives marketing authorisation for its products from UK MHRA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6c4f827-3d69-41a5-a58b-20153f67e8f1.pdf",
            "news_date": "2025-09-23 14:10:52"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Investor / Analyst meet - Pharma & Healthcare Conference - DAM Capital",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f1c9636-bc6f-4906-8554-4858b6f4dd17.pdf",
            "news_date": "2025-09-22 17:14:07"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "DISCLOSURE REGARDING 100 DAY CAMPAIGN - \"SAKSHAM NIVESHAK\"",
            "news_body": "100 days campaign for KYC and other related updations and shareholder engagement to prevent transfer of unclaimed dividends to IEPF",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e0526bb-16b7-4a24-a9dd-9d473bb54a47.pdf",
            "news_date": "2025-09-16 12:05:12"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "IEPF Newspaper Publication",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19944322-d4d4-4109-9e90-27d94a6db69b.pdf",
            "news_date": "2025-08-25 15:21:13"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Saksham Niveshak 100 Days Campaign",
            "news_body": "Please find the advertisement published by the company in regards to the campaign.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3814c57f-4d35-4d8a-9659-7b77b102a580.pdf",
            "news_date": "2025-08-25 15:19:30"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find attached publication for Saksham Niveshak Campaign.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=472a1b73-4052-4178-9852-72ddd1d78104.pdf",
            "news_date": "2025-08-25 14:50:08"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call transcript for Q1 FY 26.",
            "news_id": "029fa670-1dbc-4b29-94b8-87b523ad9389",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ce04a0c-323d-435b-9e1c-36e0c80b2242.pdf",
            "news_date": "2025-08-19 10:52:19",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call transcript for Q1 FY 26.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ce04a0c-323d-435b-9e1c-36e0c80b2242.pdf",
            "news_date": "2025-08-19 10:52:19"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limited wholly owned subsidiary in UK Relonchem Limited receives marketing authorization for its products.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1cc330b-6d01-4102-a7e6-05206cee9d2b.pdf",
            "news_date": "2025-08-18 12:17:12"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Analyst/ Investor meet audio recording",
            "news_id": "d2b97854-2a40-47c2-ba11-ee9af796102e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f0e8f16-4a38-474a-8048-739383fa268e.pdf",
            "news_date": "2025-08-13 19:13:59",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Analyst/ Investor meet audio recording",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f0e8f16-4a38-474a-8048-739383fa268e.pdf",
            "news_date": "2025-08-13 19:13:59"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Attached is the newspaper publication of the financial results for the quarter ended June 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d51f667-ef05-455e-9f7e-371322f60494.pdf",
            "news_date": "2025-08-13 11:27:50"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter Ended June 30 2025",
            "news_body": "The Board in its meeting considered and adopted Financial Results for the Quarter ended June 30 2025.",
            "news_id": "5a730a10-be40-4e24-85f1-dd66a0a323ee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6715072-2e02-4ab4-bc98-82772576b9eb.pdf",
            "news_date": "2025-08-12 13:46:11",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Results For The Quarter Ended June 30 2025",
            "news_body": "The Board in its meeting considered and adopted Financial Results for the Quarter ended June 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6715072-2e02-4ab4-bc98-82772576b9eb.pdf",
            "news_date": "2025-08-12 13:46:11"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release for Financial results Q1 FY 26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04a7892d-49a2-4f68-bae1-4e375e514137.pdf",
            "news_date": "2025-08-12 13:24:21"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation of Q1 FY 26",
            "news_id": "be1380d1-c398-4947-bc01-b08a88dd5374",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7449f75b-f499-4f5c-a133-db74f1549d81.pdf",
            "news_date": "2025-08-12 13:22:16",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation of Q1 FY 26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7449f75b-f499-4f5c-a133-db74f1549d81.pdf",
            "news_date": "2025-08-12 13:22:16"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today For Publication Of Financial Results",
            "news_body": "The Board in its meeting held today approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da311fcc-af22-440d-a8f5-62985d1dbd15.pdf",
            "news_date": "2025-08-12 13:15:30"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Voting Results For The 33Rd Annual General Meeting Of The Company.",
            "news_body": "lease find the voting results of the 33rd Annual General Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce26f4db-e2b0-4169-ac13-c6823bd40fc4.pdf",
            "news_date": "2025-08-08 18:37:20"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Scrutinizer Report along with the voting result for the 33rd AGM",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=155c52ca-961e-457f-9be0-7fb632711757.pdf",
            "news_date": "2025-08-08 17:52:45"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Proceeding of the 33rd Annual General Meeting of the Company held today.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff386e30-4e93-472f-8175-414fbb106f4e.pdf",
            "news_date": "2025-08-08 17:47:06"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Please find attached Press release for approval for Omeprazole Delayed - Release Tablets 20Mg (OTC)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58654756-cee4-4c5b-a653-8054610d5ba0.pdf",
            "news_date": "2025-08-08 10:39:59"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Kindly find enclosed intimation for Investor(s) / Analyst(s) meet for Q126",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e25b2139-09d0-4961-b437-8b7b26700228.pdf",
            "news_date": "2025-08-05 11:48:00"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Attached is the copy of Newspaper Publication of addendum to the notice of 33rd Annual General Meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8efd6527-66ae-4e84-aa92-24355e438f7c.pdf",
            "news_date": "2025-07-28 11:04:08"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Re-Appointment Of Mr. Mark Saldanha For A Period Of 5 Years With Effect From 06-10-2025",
            "news_body": "The Board in its meeting considered the reappointment of Mr. Mark Saldanha for a period of 5 years with effect from 06-10-2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f174d4f2-8e7f-46c7-a9f9-185639065401.pdf",
            "news_date": "2025-07-25 18:03:07"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "AGM",
            "caption": "Addendum To The Notice Of 33Rd Annual General Meeting",
            "news_body": "The Board of Directors have proposed one additional resolution for the approval of shareholders as attached herewith.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10b6cfdd-e7ca-4867-8e6a-23bebb0f5672.pdf",
            "news_date": "2025-07-25 17:43:39"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome without intimation",
            "caption": "Board Meeting Outcome for Outcome For Consideration And Re-Appointment Of Mr. Mark Saldanha  Subject To The Approval Of The Shareholders At The Ensuing Annual General Meeting",
            "news_body": "The Board in its meeting held today recommended the re-appointment of Mr. Mark Saldanha  subject to the approval of the shareholders at the ensuing Annual General Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f619b36b-cd81-4cdb-8a9a-b9b01e44cc81.pdf",
            "news_date": "2025-07-25 17:38:26"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Consideration And Approval Of Financial Results For The Quarter Ended June 30 2025",
            "news_body": "Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve financial results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1549171-da34-46ea-a30d-62055b97694d.pdf",
            "news_date": "2025-07-24 15:25:43"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find attached newspaper publication for the Annual General Meeting Notice",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e47e55fc-8906-44cf-b214-66b4c0e84601.pdf",
            "news_date": "2025-07-17 11:21:32"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find attached newspaper publication for the Annual General Meeting Notice",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8115c8c4-c4e2-4f4a-b8a3-b8745bd87d79.pdf",
            "news_date": "2025-07-17 11:20:05"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "Please find enclosed the report.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb68b392-24d6-426d-8a02-5d60bbae1c0a.pdf",
            "news_date": "2025-07-16 15:47:51"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Please find attached herewith the Annual Report for the Financial Year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1943f867-06b1-4f09-82b4-cd49f7aa2d97.pdf",
            "news_date": "2025-07-16 15:46:01"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "AGM",
            "caption": "Shareholders Annual General Meeting To Be Held On August 8 2025",
            "news_body": "The 33rd Annual General Meeting of the Company is proposed to be held on August 8 2025 through audio visual means to transact the business as stated in the notice.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98c992ad-b1f1-415f-aea6-231d36790bec.pdf",
            "news_date": "2025-07-16 15:37:19"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication for AGM intimation",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=175647c9-f7e8-4835-bb18-33217a9cd167.pdf",
            "news_date": "2025-07-14 10:55:00"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Date of payment of Dividend",
            "caption": "Announcement under Regulation 30 (LODR)-Date of payment of Dividend",
            "news_body": "Please find attached announcement related to the Dividend record date for the purpose of dividend.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c278b968-34f9-4ef5-9bbe-2e7427fb6b99.pdf",
            "news_date": "2025-07-11 13:19:40"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Dividend Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Dividend Updates",
            "news_body": "The Board in its meeting held today i.e. 11th July 2025 finalized the Record date as August 1 2025 for the purpose of dividend.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=910f524d-779b-48d9-8bd9-e5e6ed59f327.pdf",
            "news_date": "2025-07-11 13:16:00"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "AGM",
            "caption": "The Annual General Meeting Is Proposed To Be Held On August 8 2025.",
            "news_body": "The Board in its meeting decided the date of annual general meeting to be held on August 8 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d57a014b-bde7-471b-9916-cb6b153bc960.pdf",
            "news_date": "2025-07-11 13:10:21"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Appointment Of Secretarial Auditor For A Term Of 5 Years.",
            "news_body": "The Board considered and recommended M/s Jinesh Dedhia and associates as the secretarial auditor for the term of 5 years to the shareholders for their approval.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d139832d-cc62-444f-8b46-31c48e209992.pdf",
            "news_date": "2025-07-11 13:02:36"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "The Board Fixes August 1 2025 As The Record Date For The Purpose Of Dividend.",
            "news_body": "August 1 2025 is fixed as the record date for ascertaining the members of the Company for payment of Dividend.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43c4bdb1-896b-4be4-ae9d-67625072e98b.pdf",
            "news_date": "2025-07-11 12:51:06"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome without intimation",
            "caption": "Board Meeting Outcome for Board Meeting Outcome For Consideration And Approval Of Annual General Meeting Related Matters.",
            "news_body": "The Board in its meeting approved the Annual General Meeting related Matters and fixed August 8 2025 as the Annual General Meeting date.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ea85e90-163d-4633-9862-5040d8721743.pdf",
            "news_date": "2025-07-11 11:55:54"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Please find enclosed the certificate for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=959166be-1012-41a1-a6ea-0bddfafd8c62.pdf",
            "news_date": "2025-07-09 13:02:19"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Receipt of EIR from USFDA for Inspection conducted at manufacturing facility of Company s subsidiary Time Cap Laboratories INC",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82ea6a5c-37cd-4772-9ae9-1c781794c247.pdf",
            "news_date": "2025-06-30 12:26:58"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "The trading window for dealing in shares of the Company is being closed w.e.f. 1st July 2025 up to 48 hours after the declaration of the result for the designated person and their relatives.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a3f3818-d5ae-4572-aa17-fdbf7f14c902.pdf",
            "news_date": "2025-06-25 11:09:33"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary in the UK Relonchem Limited received Marketing Authorisation for its product Oxybutynin Hydrochloride 2.5mg/5ml oral solution from UK MHRA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46ecd449-066a-4c5c-a4f0-f5bc5440edd8.pdf",
            "news_date": "2025-06-19 09:12:05"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for OrbiMed Asia IV Mauritius FVCI Ltd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=A0773D09_8C07_4509_931E_7D3BC320B499_130347.pdf",
            "news_date": "2025-06-16 13:03:50"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Ltds wholly owned subsidiary Relonchem Ltd  receives Marketing Authorisation for its products Metformin Hydrochloride 500mg/ 5ml Oral Solution from UK MHRA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a595faa8-ef4a-4201-b331-655a92a84b87.pdf",
            "news_date": "2025-05-30 09:09:14"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "Annual secretarial compliance report for the year 2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=450cbc0c-08f7-483e-8aeb-1ee2479da5d9.pdf",
            "news_date": "2025-05-29 14:17:02"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Transcript of the conference call held on 20 May 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab69125c-8c67-406d-9ac1-8238d693da3f.pdf",
            "news_date": "2025-05-26 16:49:52"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Newspaper Advertisement Of Financial Results For The Quarter And Year Ended March 31 2025",
            "news_body": "Newspaper advertisement of audited financial results for the quarter and year ended 31 March 2025 published on 21 May 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32f79983-b838-4db8-ae54-e07d66c904db.pdf",
            "news_date": "2025-05-22 09:23:07"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform the stock exchanges that the Company has uploaded the audio recording of investor(s) / analyst(s) meet for Q4FY25 financial performance and strategy update held today i.e. May 20 2025 on the Companys website at http://marksanspharma.com/investors-meet.html",
            "news_id": "89c28192-8bd4-4f99-8a20-cfbb081b525d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d85a0812-8eb9-4f90-afa8-eb2b8693a88f.pdf",
            "news_date": "2025-05-20 21:00:18",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform the stock exchanges that the Company has uploaded the audio recording of investor(s) / analyst(s) meet for Q4FY25 financial performance and strategy update held today i.e. May 20 2025 on the Companys website at http://marksanspharma.com/investors-meet.html",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d85a0812-8eb9-4f90-afa8-eb2b8693a88f.pdf",
            "news_date": "2025-05-20 21:00:18"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Results For The Year Ended March 31 2025",
            "news_body": "Standalone and Consolidated results for the year ended March 31 2025",
            "news_id": "8143d6dc-726d-48b4-9eb2-032ea1d8a90e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ba3fcba1-d8ae-4f48-ae08-cefeb491cdc0.pdf",
            "news_date": "2025-05-19 22:04:08",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Audited Results For The Year Ended March 31 2025",
            "news_body": "Standalone and Consolidated results for the year ended March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ba3fcba1-d8ae-4f48-ae08-cefeb491cdc0.pdf",
            "news_date": "2025-05-19 22:04:08"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "The Board considered and approved the appointment of Mr. Srinivas Mishra as additional director under the category non executive and Independent Director of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c78bfa0-8ebf-4246-9de3-bb1efcfcae90.pdf",
            "news_date": "2025-05-19 21:05:12"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release attached",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1c79df4-a51f-42d4-aed6-cbf417788422.pdf",
            "news_date": "2025-05-19 20:42:50"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation attached",
            "news_id": "0154caf0-ba3d-48ad-9e94-5263bce4dddd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3ccd2d1-b84e-4cba-82bd-0082038c7d29.pdf",
            "news_date": "2025-05-19 20:40:14",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation attached",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3ccd2d1-b84e-4cba-82bd-0082038c7d29.pdf",
            "news_date": "2025-05-19 20:40:14"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Board Meeting Outcome For Consideration And Approval Of Audited Results For The Year Ended March 31 2025",
            "news_body": "The Board in its meeting considered and approved of results for the year ended March 31 2025 recommendation of dividend and other related matters",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=765bd0d2-7526-43ea-8b23-7b38dfd98ca6.pdf",
            "news_date": "2025-05-19 20:03:46"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary in UK Relonchem Limited received Marketing Authorisation for product Snnosides 7.5 mg tablets",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93bc72c7-ed69-471f-a450-a553f86b4628.pdf",
            "news_date": "2025-05-19 13:22:00"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Marksans Pharma Limiteds wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Gabapentin 50 mg/ml oral solution from UK MHRA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=222e542c-d6f4-44e0-b832-0a5dc77789bd.pdf",
            "news_date": "2025-05-15 09:12:17"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that the Company has scheduled a conference call for analysts and investors on Tuesday May 20 2025 at 05:00 PM (IST) to discuss the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=463ad30f-d211-465d-8ceb-5a411beeb2d9.pdf",
            "news_date": "2025-05-09 13:38:32"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for To Consider And Approve Audited Financial Results (Both Standalone And Consolidated) For The Quarter And Year Ended March 31 2025 And To Consider Recommendation Of Dividend On Equity Shares For The Financial Year 2024-25 If An",
            "news_body": "Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve 1. To consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended March 31 2025.\r\n2. To consider recommendation of dividend on the equity shares for the financial year 2024-25 if any.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddeb4858-f6be-4646-9677-d44fea896b9b.pdf",
            "news_date": "2025-05-08 10:51:48"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "USFDA inspection at manufacturing facility of Companys subsidiary Time-Cap Laboratories Inc.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=683db5f0-2b47-48cc-b593-57544817c0b2.pdf",
            "news_date": "2025-04-28 11:09:24"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Kindly find enclosed certificate from RTA under Reg. 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b6fefa3-6391-4b8d-bb48-4bf5ebcc5ea2.pdf",
            "news_date": "2025-04-10 12:22:26"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Cessation",
            "caption": "Announcement under Regulation 30 (LODR)-Cessation",
            "news_body": "Pursuant to Reg 30 of SEBI (LODR) Reg 2015 Mr. SR Buddharaju - Independent Director has ceased to be an Independent Director of the Company upon completion of his tenure of two terms of 5 consecutive years w.e.f end of the day on March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81a32e1c-9a7c-40bc-b793-c8935ff180fc.pdf",
            "news_date": "2025-03-31 16:54:47"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Kindly find enclosed intimation for closure of trading window under SEBI (Prohibition of Insider Trading) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=acee1665-8abd-4d72-9ce0-52d3c20afeed.pdf",
            "news_date": "2025-03-26 16:24:15"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "This is to inform that official of the Company will participate in the investor/analyst conference i.e. Motilal Oswal India Ideation conference on 25 March 2025 at 10:00 am at Grand Hyatt Mumbai.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09d37f6f-629a-46dc-9a98-0075dfdbb3ff.pdf",
            "news_date": "2025-03-21 11:12:42"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Kindly find enclosed press release dated 20th March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=182adac0-070b-40e3-b2fa-30f1a6a1ccc2.pdf",
            "news_date": "2025-03-20 11:14:19"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Kindly find attached",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8fd0f4b5-bb12-47c5-80c8-8a6eb64670d3.pdf",
            "news_date": "2025-03-19 12:15:43"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Credit Rating",
            "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
            "news_body": "Kindly find enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c761c393-d7f7-42f8-9314-1a544526b574.pdf",
            "news_date": "2025-03-05 14:54:12"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Kindly find enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d047819-17b8-4a37-b726-53faae7cdb55.pdf",
            "news_date": "2025-02-25 12:20:26"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find enclosed",
            "news_id": "1941edc9-6c5b-4e29-b874-2924a31b465f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de9e78c7-d9a6-47b3-99fb-3024051aaec2.pdf",
            "news_date": "2025-02-25 12:08:52",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 3285,
            "bse_code": 524404,
            "isin": "INE750C01026",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de9e78c7-d9a6-47b3-99fb-3024051aaec2.pdf",
            "news_date": "2025-02-25 12:08:52"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find enclosed",
            "news_id": "860974fc-baed-408e-9edf-d73a6fa0ca35",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3a9c046-2eec-42a4-af77-ed6caa22efd3.pdf",
            "news_date": "2025-02-25 12:03:56",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Quarter And Nine Months Ended December 31 2024",
            "news_body": "Kindly find enclosed",
            "news_id": "7128ab42-ad9e-4fbb-8e15-cd86c9e8cb72",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac54d7f2-a381-4c74-89a4-fb173e8de227.pdf",
            "news_date": "2025-02-11 20:53:22",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Kindly find enclosed investor presentation",
            "news_id": "d25fa182-3ae9-475a-a946-f19e6151f897",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c3e40b8-5740-4fae-be66-d0d040b09b93.pdf",
            "news_date": "2025-02-11 20:46:32",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find enclosed earnings call transcript for Q2FY25 financial performance and strategy update",
            "news_id": "5a71316e-c52d-40cb-9300-9cf3ebe6b75f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25a27757-30ac-4034-ac29-1c4f9596f2c6.pdf",
            "news_date": "2024-11-25 10:34:46",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Quarter And Half Year Ended September 30, 2024",
            "news_body": "Kindly find enclosed",
            "news_id": "40a6f7ae-c89b-4592-a4ca-b373326e7c87",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95a8d751-081a-4ca9-a055-b69d10aecddb.pdf",
            "news_date": "2024-11-12 13:12:28",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "PFA",
            "news_id": "cfcb4104-f968-4dad-aec9-b1f32be0a796",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=421eca1a-2738-45e2-b849-1fa434718354.pdf",
            "news_date": "2024-11-12 13:04:40",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find encloed",
            "news_id": "89a8ecf7-637b-480d-b154-bc84324316bd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb086858-4995-41a6-adf5-d076c0535e71.pdf",
            "news_date": "2024-08-22 14:24:35",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Kindly find enclosed",
            "news_id": "b41fb742-955a-4b0e-a347-4000da44000a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52a65efa-c5b2-4cea-b4c8-af52a2d2dcb7.pdf",
            "news_date": "2024-08-13 19:58:27",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Result For Quarter Ended June 30, 2024",
            "news_body": "Kindly find enclosed",
            "news_id": "6e5ff8ee-4e69-4582-83cb-5696ec8c62e0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fb74909-d5a1-4434-8554-54d08cbac240.pdf",
            "news_date": "2024-08-13 19:55:11",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find attached transcript of earnings call Q4FY24",
            "news_id": "3d60e361-5e26-4bde-9b9d-e8c102832dd8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e63d207-a628-43f3-b3ad-49088a4242ca.pdf",
            "news_date": "2024-06-05 17:24:56",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on financial results for FY24",
            "news_id": "626a7e49-a1d5-41ad-a07b-850dce3641cd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f11415cc-06c3-4ce6-a99f-d7cd31980047.pdf",
            "news_date": "2024-05-30 12:08:45",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For FY24",
            "news_body": "Kindly find enclosed the results for FY24",
            "news_id": "74b2809f-071e-493d-8e53-320f16d6d16e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=63997228-0914-401a-a72e-24d4c7728857.pdf",
            "news_date": "2024-05-30 12:05:47",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Kindly find enclosed the transcript of investors/analysts meet for Q3FY24 financial performance",
            "news_id": "10d88ced-8a3b-4abb-89d7-7b97d30a87c6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=759b003c-c3fe-4e50-a2df-cb8d111c7e8b.pdf",
            "news_date": "2024-02-20 14:30:30",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording link of investors/analysts meet fir Q3FY24",
            "news_id": "2333f2be-9f9b-4f91-a719-e45db5bc0cb6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7aeb6f7-8d24-4d02-b4fe-bfa6381eb42e.pdf",
            "news_date": "2024-02-14 18:26:40",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Quarterly Financial Results For Quarter Ended December 31, 2023",
            "news_body": "Quarterly financial results for quarter ended December 31, 2023",
            "news_id": "51c1004e-dcd7-452b-aa0c-666e34478e26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=120f7fbb-d008-4d87-8fca-4d2124703641.pdf",
            "news_date": "2024-02-13 14:51:27",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation on financial results for quarter ended December 31, 2024",
            "news_id": "5dc45b25-b2c6-4f6e-9e40-1f197cd42ac8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=84758428-9feb-4bea-84ca-a2a18c5eb159.pdf",
            "news_date": "2024-02-13 14:40:32",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to regulation 30, please find enclosed the transcript of the investors / analysts meet for Q2FY2024 held on November 09, 2023",
            "news_id": "324b6ced-86bd-46d9-b1a5-dfa399891d43",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c84979e4-afdd-4054-9077-8f9413709883.pdf",
            "news_date": "2023-11-16 12:25:17",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to regulation 30 of SEBI (LODR) regulations, 2015, the Company has uploaded the audio recording of investors/analysts meet for Q2FY24 financial performance and strategy update held today i.e. November 09, 2023 on the Company website",
            "news_id": "f2b8f48a-69a5-4d13-8c9d-ab49b3ff2e9e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddab8503-2adb-4c89-953d-8500f33817b0.pdf",
            "news_date": "2023-11-09 19:28:38",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Quarterly And Half Yearly Results For Period Ended September 30, 2023",
            "news_body": "Quarterly and half yearly results",
            "news_id": "4b4e59a3-4459-4fa3-9a97-d15451d0d48e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d644caa9-2a2f-491d-83d2-8d77ebde25a2.pdf",
            "news_date": "2023-11-09 13:29:26",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation for Q2FY24",
            "news_id": "3dee1f7a-a767-4e2b-9004-7c07a5b67b63",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97eaffe1-a051-4e09-8eea-e06cb132b40e.pdf",
            "news_date": "2023-11-09 13:12:39",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to regulation 30 read with para A of schedule III of SEBI (LODR) Regulations, 2015, kindly find enclosed the transcript of the investors / analysts meet for Q1FY2024.The information is also available on the website of the Company.",
            "news_id": "1dae7b1c-48f7-4f94-ba5f-0659d275d15a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3172879-2d5d-49c3-afd1-20d98a85a37b.pdf",
            "news_date": "2023-08-22 14:13:47",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the aforesaid FinancialResults Conference Call is hosted on the website of the Company under the following link:http://marksanspharma.com/investors-meet.html",
            "news_id": "22398ec0-1540-4228-8284-2901425bc855",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39465d25-3902-47b5-8109-60ce8b0d318c.pdf",
            "news_date": "2023-08-17 09:20:56",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investors presentation on Financial results for quarter ended June 30, 2023",
            "news_id": "3799c570-09d4-48c9-9459-1a8a3d36f096",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4db23e9-d535-4e51-be8f-6a2af3f7e549.pdf",
            "news_date": "2023-08-11 18:35:09",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting - Unaudited Consolidated And Standalone Financial Results For Quarter Ended June 30, 2023",
            "news_body": "Unaudited Consolidated and standalone financial results along with limited review reports for quarter ended June 30, 2023",
            "news_id": "84fbc614-0119-499d-b8f3-7e5a61e6439f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=291eed13-3d4c-4b83-96d8-eb4abda741e4.pdf",
            "news_date": "2023-08-11 18:30:45",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q4 FY23 Earnings Conference Call held on May 31, 2023",
            "news_id": "7a7ca194-e3ea-4a3d-a24a-a4639aedb9e0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=542f528d-dee0-4718-9ab9-10f1183f4f9e.pdf",
            "news_date": "2023-06-07 11:18:06",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Announcement Under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the aforesaid Financial Results Conference Call is hosted on the website of the Company under the following link: http://marksanspharma.com/investors-meet.html",
            "news_id": "738bb014-4bb2-4744-9f7c-32c54ee8cbf5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f2c2a18-0891-41b0-b835-cde464a3e869.pdf",
            "news_date": "2023-05-31 18:44:07",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4FY23 and FY23",
            "news_id": "c21b1f26-fb75-43e4-8c2a-60e009a48386",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=acb3439c-78f7-43a7-99aa-f0468efb43b3.pdf",
            "news_date": "2023-05-30 13:58:16",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2023 And Auditors Report Thereon.",
            "news_body": "Attached herewith Audited Financial Results for the quarter and financial year ended 31st March, 2023 and Auditors Report thereon.",
            "news_id": "c6cf303d-f626-4be1-8800-e5176195485c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b6dbe92b-4375-44aa-aed4-e132a47caf4f.pdf",
            "news_date": "2023-05-30 13:50:56",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q3 FY23 Earnings Conference Call held on February 14, 2023",
            "news_id": "c918c8d5-c332-4e13-8d79-244ac4086382",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b694ba05-6daa-42eb-b291-b861dde45b28.pdf",
            "news_date": "2023-02-21 11:07:57",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the aforesaid Financial Results Conference Call is hosted on the website of the Company under the following link: http://marksanspharma.com/investors-meet.html",
            "news_id": "230f501b-d240-477e-a6ba-d1b6a6ea122e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b1ede72-4b11-410d-bb2c-7fd55ea476be.pdf",
            "news_date": "2023-02-14 18:26:07",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q3FY23",
            "news_id": "bc337387-c6a4-4f46-a61f-11be9d1bfe01",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2eb5133-5eed-4357-9f94-caef44bf7a3b.pdf",
            "news_date": "2023-02-13 13:45:06",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2022 And Limited Review Report Thereon",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and nine months ended 31st December, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 13th February, 2023 along with Limited Review Reports given by statutory auditor of the Company.<BR>",
            "news_id": "04900a61-40a7-4ee8-9db0-05fdb2f16502",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c13c6d23-ca98-44b7-9882-031b0f02a57c.pdf",
            "news_date": "2023-02-13 13:40:24",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015",
            "news_body": "Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of related party transactions for the half year ended 30th September, 2022.",
            "news_id": "b028c773-d888-44dc-ab8e-dc83b1e21e9f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06a7de6a-63bd-4bc6-a819-1749b6dbf09b.pdf",
            "news_date": "2022-11-25 11:26:20",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q2 FY23 Earnings Conference Call held on November 16, 2022.",
            "news_id": "6038921f-3a47-4c84-8099-b1ca75a73a81",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=96366b09-0e35-4d56-910f-5f957c45d023.pdf",
            "news_date": "2022-11-21 17:12:04",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the Q2FY23 & H1FY23 Results Conference Call is hosted on the website of the Company under the following link: http://marksanspharma.com/investors-meet.htmI",
            "news_id": "3a2ffa24-6042-4bb5-9901-a640f2de69d8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=821b9ac6-2348-46a0-92c2-94e49519f3ba.pdf",
            "news_date": "2022-11-16 21:19:05",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation H1FY23 & Q2FY23",
            "news_id": "7163901f-3258-4653-9d4a-ed9dc0a19cae",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5e2545e-8ce9-4408-9376-a20de7d72d48.pdf",
            "news_date": "2022-11-14 19:56:54",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half-Year Ended 30Th September, 2022 And Limited Review Report Thereon.",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half-year ended 30th September, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 14th November, 2022 along with Limited Review Reports given by statutory auditor of the Company.<BR> <BR> The meeting commenced at 06:45 p.m. and concluded at 07:45 p.m.<BR>",
            "news_id": "0ee9717f-bb4e-4a9d-a7eb-d50927b9c44c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0587c961-88fc-4dfc-8f0c-ff85546e4f01.pdf",
            "news_date": "2022-11-14 19:49:12",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q1FY23 Earnings Conference Call held on August 16, 2022.",
            "news_id": "14cce193-dc31-44c7-a1db-f92eb0175679",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22cfbd11-3572-4d9c-b28d-1fb15c52cc7c.pdf",
            "news_date": "2022-08-19 16:39:58",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q1FY23",
            "news_id": "66e4f33a-ea8d-48f6-83fb-11de78284e60",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed77e14b-16ce-4041-98da-f93cb2275822.pdf",
            "news_date": "2022-08-13 19:57:28",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Limited   Review Report Thereon",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter ended 30th June, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 13th August, 2022 along with Limited Review Reports given by statutory auditor of the Company.<BR> <BR> The meeting commenced at 6:20 p.m. and concluded at 7:40 p.m.",
            "news_id": "dc08047b-4c92-4cfa-9364-806573091f09",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9882a73-6e6b-48b2-9ffb-e768a613dbbe.pdf",
            "news_date": "2022-08-13 19:55:45",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015",
            "news_body": "Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of related party transactions of the Company and its subsidiaries for the half year ended 31st March, 2022.",
            "news_id": "98135a9e-2cf4-4c5e-89c0-bf59c49ef8eb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa3a3f46-19d6-4619-9d99-60fb65466e9a.pdf",
            "news_date": "2022-06-10 11:43:49",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q4 &FY22 Earnings Conference Call held on June 1, 2022.",
            "news_id": "4ba4f59d-3af5-4130-aa6d-085cd9b30097",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36014887-210a-4f0d-b069-48aa626b5f58.pdf",
            "news_date": "2022-06-06 12:29:30",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Q4&FY22 Results Conference Call is hosted on the website of the Company at http://marksanspharma.com/investors-meet.html",
            "news_id": "2959ae48-dfe4-4a87-a6bd-fc85b537954c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5582216-6d51-4337-ae21-4f3bdad10e87.pdf",
            "news_date": "2022-06-01 22:21:13",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4 & FY22",
            "news_id": "f5b61553-e2ba-424b-beb2-2f8f5910076d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fcdcfc07-efb0-4c30-afb4-f28f5492de2d.pdf",
            "news_date": "2022-05-30 20:15:21",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2022 And Auditors Report Thereon",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Financial Results (both Standalone and Consolidated) for the quarter and financial year ended 31st March, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 30th May, 2022 along with Auditors Report thereon.<BR> <BR> The meeting commenced at 7:17 p.m. and concluded at 8:00 p.m.<BR> <BR> In this connection, we hereby confirm that the Statutory Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2022 (both Standalone and Consolidated) with unmodified opinion.<BR> <BR> <BR>",
            "news_id": "192a40a1-aaac-4668-a1c2-385c9b142513",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22ad61a2-19b8-4743-a923-ace6f8deb41c.pdf",
            "news_date": "2022-05-30 20:11:40",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached an investors presentation of Marksans Pharma Limited for Q3 & 9M FY22.",
            "news_id": "10ee3702-60cc-411e-85f6-7a927d9044a2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1e9b58e-4350-43dd-814c-7619399583f1.pdf",
            "news_date": "2022-02-11 12:54:51",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Third Quarter Ended 31St December, 2021 And Limited Review Reports Thereon.",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the third quarter ended 31st December, 2021 which have been approved by the Board of Directors at its meeting held today i.e. 11th February, 2022 along with Limited Review Reports given by Statutory auditor of the Company. <BR> The meeting commenced at 12:00 noon and concluded at 12:45 p.m.",
            "news_id": "336f3775-ff78-4844-b2b6-fa2b18335427",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36ae1a76-804c-475a-8651-dfad1ade2ca8.pdf",
            "news_date": "2022-02-11 12:52:40",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached an investors presentation of Marksans Pharma Limited for Q2 & H1 FY22.",
            "news_id": "154bfe9f-31d8-46a5-8b58-51c2ae337e4d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b438d166-1877-44a3-920c-4ff0316d2195.pdf",
            "news_date": "2021-11-10 10:59:38",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half-Year Ended 30Th September, 2021 And Limited Review Reports Thereon",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half-year ended 30th September, 2021 which have been approved by the Board of Directors at its meeting held today i.e. 10th November, 2021 along with Limited Review Reports given by statutory auditor of the Company.<BR> <BR> The meeting commenced at 9:30 a.m. and concluded at 10:50 a.m.",
            "news_id": "90b4241b-9f8a-4556-af6a-9dd61f9b84b8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a8bd4f7-b44e-44a1-9a36-949f105982f5.pdf",
            "news_date": "2021-11-10 10:56:00",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached an investors presentation of Marksans Pharma Limited for Q1 FY22.",
            "news_id": "8712842a-5b1b-4729-a8d6-9fffb1c8021e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=035cffb9-ca8c-4dee-864a-dd2b94f8a675.pdf",
            "news_date": "2021-08-11 12:22:21",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th June, 2021 And Limited Review Reports Thereon.",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter ended 30th June, 2021 approved by the Board of Directors at its meeting held today i.e. 11th August, 2021 along with Limited Review Reports given by statutory auditor of the Company.<BR> <BR> The meeting commenced at 11:00 a.m. and concluded at 12:10 p.m.",
            "news_id": "987578d3-72e4-41e7-aa88-42d1fe11646f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d788ff3d-8178-4869-bfd6-72e90c988039.pdf",
            "news_date": "2021-08-11 12:14:37",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 31St March, 2021",
            "news_body": "Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosures of related party transactions for the half year ended 31st March, 2021. The financial results for the quarter and year ended 31st March, 2021 both standalone and consolidated were published on 31st May, 2021.",
            "news_id": "11f5e015-06f2-445d-9359-6008b5feaa81",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc0ed3b1-146f-49be-9f23-92eede0a633e.pdf",
            "news_date": "2021-06-28 12:36:57",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Attached pl find Investors Presentation for the year ended 31st March, 2021",
            "news_id": "a367f6ab-7e1a-46d3-9ba9-1758ab983c50",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4bdc92a-4808-4723-baba-52800867f762.pdf",
            "news_date": "2021-05-31 12:43:04",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "MARKSANS",
            "disp": "Marksans Pharma",
            "bse_code": 524404,
            "isin": "INE750C01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2021 And Auditors Report Thereon.",
            "news_body": "In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Financial Results (both Standalone and Consolidated) for the quarter and financial year ended 31st March, 2021 approved by the Board of Directors at its meeting held today i.e. 31st May, 2021 along with Auditors Report thereon.<BR> <BR> The meeting commenced at 11:00 a.m. and concluded at 12:25 p.m.   <BR> <BR> In this connection, we hereby confirm that the Statutory Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2021 (both Standalone and Consolidated) with unmodified opinion.",
            "news_id": "f966506f-e05f-4f1a-ac22-39d7f125e515",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f844cd88-2a8f-436c-8171-f4dd798c36a7.pdf",
            "news_date": "2021-05-31 12:35:09",
            "seo": "marksans-pharma-ltd",
            "ltp": 187.54,
            "ch": 0.549999999999983,
            "pch": 0.29413337611636076,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 10579,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}